Providence Health & Service joined Excel Venture Management to fund precision oncology analysis company N-of-One's latest round, which will support sales and marketing.
N-of-One, a US-based developer of technology that can help determine the best course of cancer treatment, has secured $7m in a series B round featuring corporate venturing unit Providence Ventures
Providence Ventures, the strategic investment arm of care provider Providence Health & Service, provided the funding alongside venture capital firm Excel Venture Management.
N-of-One’s technology analyses each cancer patient’s unique molecular profile to determine the best course of precision oncology treatment. It will use the series B capital to build up its sales and marketing capabilities.
The company previously raised $2.75m in debt and equity financing, according to regulatory filings.
